Zosano Pharma Co. (NASDAQ:ZSAN – Get Rating) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 370,200 shares, a decline of 96.2% from the March 31st total of 9,620,000 shares. Approximately 7.6% of the company’s stock are sold short. Based on an average daily trading volume, of 489,100 shares, the days-to-cover ratio is presently 0.8 days.
ZSAN has been the subject of several recent analyst reports. StockNews.com assumed coverage on shares of Zosano Pharma in a research report on Tuesday, April 19th. They set a “sell” rating for the company. BTIG Research downgraded shares of Zosano Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 23rd.
A number of hedge funds and other institutional investors have recently modified their holdings of ZSAN. Morgan Stanley grew its stake in Zosano Pharma by 954.9% in the 1st quarter. Morgan Stanley now owns 45,879 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 41,530 shares during the last quarter. Millennium Management LLC acquired a new stake in Zosano Pharma in the 2nd quarter valued at about $65,000. Barclays PLC grew its stake in Zosano Pharma by 50.0% in the 3rd quarter. Barclays PLC now owns 300,000 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 100,000 shares during the last quarter. Citadel Advisors LLC boosted its stake in shares of Zosano Pharma by 263.9% during the 3rd quarter. Citadel Advisors LLC now owns 146,166 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 105,999 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in shares of Zosano Pharma by 95.7% during the 3rd quarter. LPL Financial LLC now owns 58,700 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 28,700 shares during the last quarter. 10.57% of the stock is currently owned by hedge funds and other institutional investors.
Zosano Pharma (NASDAQ:ZSAN – Get Rating) last posted its quarterly earnings results on Thursday, March 17th. The biotechnology company reported ($2.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.45) by $0.35. Zosano Pharma had a negative net margin of 3,812.10% and a negative return on equity of 80.12%. The business had revenue of $0.09 million for the quarter. As a group, analysts expect that Zosano Pharma will post -7.69 earnings per share for the current year.
Zosano Pharma Company Profile (Get Rating)
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine.
- Get a free copy of the StockNews.com research report on Zosano Pharma (ZSAN)
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.